4-Phenylpiperazine Derivatives with Functionalized Linkers for D3 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing dopamine D3 receptor-selective compounds that can penetrate the blood-brain barrier effectively while avoiding the challenges of high doses required for behavioral activity, due to low permeability, high peripheral metabolism, or large uptake in other organs, and achieving high selectivity over D2 receptors.
Innovation Solution
Designing chemical compounds with specific functional groups, such as hydroxyl or acetyl substitutions in the butylamide linking chain of 4-phenylpiperazine derivatives, which enhance D3 receptor affinity and selectivity, improve water solubility, and reduce lipophilicity, allowing for better brain penetration and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If relatively large molecules with unsubstituted 4-carbon chains are used to achieve high D3 selectivity, then D3/D2 selectivity is improved, but molecular size and complexity increase
Solution Approach 1:
The patent applies parameter changes by systematically modifying the linker chain substituents (adding hydroxyl, acetyl, or carboxyl groups at different positions) to optimize the balance between D3 selectivity and molecular properties. This allows achieving high selectivity with smaller, more optimized molecules rather than relying on large unsubstituted chains
Solution Approach 2:
The patent introduces functional groups at specific local positions (alpha, beta, gamma, or delta carbons of the butyl chain) to create localized interactions with the D3 receptor binding site. This targeted functionalization achieves high selectivity through specific local interactions rather than requiring overall large molecular size
2Reliability
If high doses of D3-selective agents are administered, then behavioral activity is achieved, but peripheral metabolism and off-target effects increase
Solution Approach 1:
The patent modifies physicochemical parameters (logP, polar surface area, molecular weight) by introducing polar functional groups to optimize brain penetration and reduce peripheral clearance, enabling effective doses with lower peripheral metabolism
Solution Approach 2:
The patent introduces polar functional groups at specific positions on the linker chain to enhance water solubility and brain penetration locally, which improves bioavailability and reduces the required dose, thereby minimizing peripheral metabolic burden
3Speed
If lipophilicity is increased to improve membrane penetration, then BBB permeability is improved, but water solubility decreases
Solution Approach 1:
The patent systematically adjusts the logP parameter by introducing polar functional groups (hydroxyl, acetyl, carboxyl) to optimize the balance between lipophilicity for membrane penetration and hydrophilicity for water solubility, achieving optimal bioavailability
Solution Approach 2:
The patent creates composite molecular structures combining lipophilic regions (phenylpiperazine core, aromatic groups) with hydrophilic regions (polar functional groups on linker), enabling both membrane penetration and water solubility through amphiphilic character
Data Source
AI summary
Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at D3 receptors and achieve high selectivity over D2 and D4 receptors.